GlassScriptPhysician profile
Spyro D Analytis
NPI 1407953441
$5,449.29
in general payments reported to CMS, 2019-2025
29 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $512 · 2021: $944 · 2022: $946 · 2023: $422 · 2024: $806 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,100.03 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $550.45 | 2019-2022 | |
| Amgen INC. | $475.83 | 2019-2021 | |
| Novo Nordisk INC | $380.90 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $293.56 | 2019-2022 | |
| Abbvie INC. | $291.34 | 2021-2024 | Ubrelvy, Synthroid |
| Sanofi-Aventis U.S. LLC | $250.32 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $221.59 | 2019-2020 | |
| Abbott Laboratories | $164.74 | 2022-2023 | Freestyle Libre 3 |
| Allergan, INC. | $159.25 | 2019-2020 | |
| Amarin Pharma, INC. | $158.17 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.12 | 2022-2024 | |
| Edwards Lifesciences Corporation | $133.62 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Aimmune Therapeutics, INC. | $124.99 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $119.42 | 2021 | |
| Axsome Therapeutics, INC. | $110.50 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $105.01 | 2019-2021 | |
| Mylan Specialty L.P. | $85.25 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $59.23 | 2022-2023 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $48.52 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.08 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $23.56 | 2019 | |
| Astellas Pharma US INC | $23.50 | 2019 | |
| Pfizer INC. | $16.62 | 2023 | |
| Inspire Medical Systems, INC. | $16.55 | 2023 | Inspire |
| Biogen, INC. | $14.38 | 2021 | |
| Philips North America LLC | $12.94 | 2019 | |
| Grifols USA, LLC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spyro Analytis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.